AMI in Medical Technology

Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine

Data from landmark trial provide important insight for physicians in treating heart attack patients NATICK, Mass., May 6 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed the publication of results from the HORIZONS AMI trial in this week's issue of the New...

Adoption of PCI in AMI Patients to Drive Drug-Eluting Stent Use

Nearly 150,000 PCIs Were Performed on AMI Patients in 2008, According to Millennium Research Group WALTHAM, Mass., Feb. 18 /PRNewswire/ -- According to Millennium Research Group's (MRG's) US Markets for Interventional Cardiology Devices 2009 report, the use of drug-eluting stents will conti...

HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients

Landmark trial provides new insight for physicians NATICK, Mass. and WASHINGTON, Oct. 15 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced results from an analysis of the HORIZONS AMI trial. The HORIZONS AMI trial, sponsored by the Cardiovascular ...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

... and the gain it recognized on the sale of Ibis to ami earlier this year. Accounting rules require Isis ...cial statements as a result of the sale of Ibis to ami in January 2009. Net income from discontinued ope...tatement of Operations. Since the sale of Ibis to ami was a discrete event that occurred in the first qu...

AMA Foundation Announces Seed Grant Research Recipients

...akagawa, M.D., University of California at San Francisco , San Francisco, Calif. Giang Nguyen, Albany Medical College , Albany, N.Y. ami Raval, M.D., Tufts Medical Center, Boston, Mass. Noah Rodriguez, M.D., Harvard Medical School , Boston, Mass. Ming-Sing Si, M.D., Un...

Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008

... issue a press release at this time. -- HORIZONS ami data. At 11:00 a.m., Gregg W. Stone, M.D., will pr...ardial Infarction" in the Main Arena. The HORIZONS ami trial is a randomized, controlled clinical trial d...compare TAXUS stents to bare-metal stents in 3,400 ami (acute myocardial infarction) patients. The Compan...

Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy

... use of human cells in preclinical studies. These results are indicative of cardiomyocyte regeneration and suggest that the injection of ADSCs after ami may have the potential to help the infarcted heart return to normal function. "The study data suggest that injection of adipose-derived stem cells d...

CellCyte Genetics Signs Collaborative Agreement With Northwestern University's Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCyte's CCG-TH30 Product Candidate

... candidate. The goal of the study is to evaluate the functional benefit of the CCG-TH30 therapy in a disease model outcome study representative of the ami (heart attack) indication. Douglas W. Losordo, M.D., a leader in cardiovascular cell therapy research and Director of Feinberg Cardiovascular Research...

Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents

...rly stent thrombosis rate of 1.7% and no reported thrombotic events from one to six months. As part of an extended registry study, 321 patients with ami were followed for one year. Even with the larger patient group, the MACE rate was 13.1% at one year with no mortality beyond the first month. The earl...

Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008

... Other Data Presentations to Focus on Use of Pro-Healing Stent with ami Patients and Those Who Cannot Tolerate Dual-Antiplatelet Therapy HONG KONG, May 8 /PRNewswire/ -- Twelve-month follow-up data from both a randomi...

Clinical Impact of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology

...y by Federico Piscione, M.D., of Federico II University, Naples, from 1:35 p.m.-1:55 p.m. -- A presentation about the selection of stents in ami patients by Harry Suryapranata, M.D., of Isala Klinieken, Zwolle, The Netherlands, from 1:55 p.m.-2:15 p.m. -- A Q&A session followed by clo...

U.S. Meat Industry Will Respond to World Cancer Research Fund Report

...iation representing U.S. meat and poultry packers and processors. To arrange an interview with Dr. Huffman, call 703/801-2238 or jriley@meatami.com. ami urged reporters to ask this critical question: How does WCRF reconcile claims of an association between red meat and colon cancer when the largest s...

American Meat Institute Calls WCRF Panel Recommendations on Meat Consumption Extreme and Unfounded

...sions are extreme, unfounded and out of step with dietary guidelines," said ami Foundation Vice President of Scientific Affairs Randy Huffman, Ph.D. "Headl...ww.meatpoultrynutrition.org or http://www.meatsafety.org . Media note: ami Foundation Vice President of Scientific Affairs Dr. Randy Huffman is availa...

OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007

...s an alternative to drug-eluting stents, includes: - Interventional Strategies and Adjunct Pharmacology in ACS and AMI; Should Specialized DES for ami be Developed? Early Experience with EPC Capture Technology; Jan Henk Dambrink, M.D., Ph.D., Department of Cardiology, ISALA Klinieken, Hospital ...

BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality

... injection. Patients who have undergone an acute MI (AMI) with severe heart damage are the most likely to benefit from BL-1040. Approximately 40% of ami patients develop left ventricle dilatation or heart failure, which carries a substantially greater mortality risk. This population includes approximat...

Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients With Relapsing Multiple Sclerosis

... Public Affairs,+1-617-914-6524, or investors, Eric S. Hoffman, Ph.D., Associate Director,Investor Relations, +1-617-679-2812, both of Biogen Idec; or ami Knoefler,Corporate and Investor Relations, +1-510-284-8851, or ,or Jean Suzuki, Corporate Relations, +1-510-574-1550, or, both of PDL BioPharma

Hospitalization Rates for Coronary Artery Disease Decline in the U.S.

... 591,000 in 2005 -- a decline from 309 to 266 per 100,000 persons. This was driven by a decrease in the more severe transmural form of ami from 118 to 87 per 100,000. - Hospitalization rates for coronary revascularization declined from 382 to 358 per 100,000 persons from 200...

Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents

... patient enrollment in the trial, which is a single-center, prospective, non-randomized study of 60 patients with ST segment elevation ami with one infarct lesion in a single vessel. The primary endpoint is stent thrombosis at 30 days post-procedure. Patient follow-up is u...